The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform

Peter S. Zammit - One of the best experts on this subject based on the ideXlab platform.

  • A modified human Myogenin promoter that is highly active in alveolar rhabdomyosarcoma
    Cancer gene therapy, 2020
    Co-Authors: Johanna Pruller, Isabella Hofer, Massimo Ganassi, Philipp Heher, Michelle T., Peter S. Zammit
    Abstract:

    Rhabdomyosarcoma is a rare childhood soft tissue cancer whose cells resemble poorly differentiated skeletal muscle, expressing myogenic proteins including MYOGENIN. Alveolar rhabdomyosarcoma (ARMS) accounts for ~40% of cases and is associated with a poorer prognosis than other rhabdomyosarcoma variants, especially if containing the chromosomal translocation generating the PAX3-FOXO1 hybrid transcription factor. Metastasis is commonly present at diagnosis, with a Five-Year Survival Rate of

  • A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
    Cancer Gene Therapy, 2020
    Co-Authors: Johanna Pruller, Isabella Hofer, Massimo Ganassi, Philipp Heher, Peter S. Zammit
    Abstract:

    Rhabdomyosarcoma is a rare childhood soft tissue cancer whose cells resemble poorly differentiated skeletal muscle, expressing myogenic proteins including MYOGENIN. Alveolar rhabdomyosarcoma (ARMS) accounts for ~40% of cases and is associated with a poorer prognosis than other rhabdomyosarcoma variants, especially if containing the chromosomal translocation generating the PAX3-FOXO1 hybrid transcription factor. Metastasis is commonly present at diagnosis, with a Five-Year Survival Rate of

Johanna Pruller - One of the best experts on this subject based on the ideXlab platform.

  • A modified human Myogenin promoter that is highly active in alveolar rhabdomyosarcoma
    Cancer gene therapy, 2020
    Co-Authors: Johanna Pruller, Isabella Hofer, Massimo Ganassi, Philipp Heher, Michelle T., Peter S. Zammit
    Abstract:

    Rhabdomyosarcoma is a rare childhood soft tissue cancer whose cells resemble poorly differentiated skeletal muscle, expressing myogenic proteins including MYOGENIN. Alveolar rhabdomyosarcoma (ARMS) accounts for ~40% of cases and is associated with a poorer prognosis than other rhabdomyosarcoma variants, especially if containing the chromosomal translocation generating the PAX3-FOXO1 hybrid transcription factor. Metastasis is commonly present at diagnosis, with a Five-Year Survival Rate of

  • A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
    Cancer Gene Therapy, 2020
    Co-Authors: Johanna Pruller, Isabella Hofer, Massimo Ganassi, Philipp Heher, Peter S. Zammit
    Abstract:

    Rhabdomyosarcoma is a rare childhood soft tissue cancer whose cells resemble poorly differentiated skeletal muscle, expressing myogenic proteins including MYOGENIN. Alveolar rhabdomyosarcoma (ARMS) accounts for ~40% of cases and is associated with a poorer prognosis than other rhabdomyosarcoma variants, especially if containing the chromosomal translocation generating the PAX3-FOXO1 hybrid transcription factor. Metastasis is commonly present at diagnosis, with a Five-Year Survival Rate of

Qing Sanhu - One of the best experts on this subject based on the ideXlab platform.

  • Relationship of prognosis of rectal cancer with surgical procedures and hyperthermic perfusion chemotherapy
    Chinese Journal of Gastrointestinal Surgery, 2001
    Co-Authors: Qing Sanhu
    Abstract:

    Objective To investigate the relationship of the prognosis of rectal cancer with surgical procedures and thermoperfusion chemotherapy.Methods All 860 cases with rectal cancer treated by operation were analyzed retrospectively. Results Of 860 patients, Dixon′s operation was performed in 510 cases, Mile′s operation in 325 cases and local rectomy in 25 cases. Local recurrence Rate and five year Survival Rate were 11 8%and 50 8%respectively after Dixon′s operation, 11 1%and 56 3%after Miles′s operation. Compared with operations before December 1990, the local recurrence Rate decreased(14 3%vs 7.3%) and the five year Survival Rate increased(30 4%vs 64.9%) significantly after December 1990 when hyperthermic perfusion chemotherapy was developed. Conclusions Surgical procedures of rectal cancer should be selected strictly according to pathological grading, cytological type,length of distal resection margin and the size of carcinoma. Correct operation and hyperthermic peritoneal perfusion chemotherapy can improve the prognosis, reduce the recurrent Rate and increase the five year Survival Rate of patients with rectal cancer.

D. Nisichenko - One of the best experts on this subject based on the ideXlab platform.

Massimo Ganassi - One of the best experts on this subject based on the ideXlab platform.

  • A modified human Myogenin promoter that is highly active in alveolar rhabdomyosarcoma
    Cancer gene therapy, 2020
    Co-Authors: Johanna Pruller, Isabella Hofer, Massimo Ganassi, Philipp Heher, Michelle T., Peter S. Zammit
    Abstract:

    Rhabdomyosarcoma is a rare childhood soft tissue cancer whose cells resemble poorly differentiated skeletal muscle, expressing myogenic proteins including MYOGENIN. Alveolar rhabdomyosarcoma (ARMS) accounts for ~40% of cases and is associated with a poorer prognosis than other rhabdomyosarcoma variants, especially if containing the chromosomal translocation generating the PAX3-FOXO1 hybrid transcription factor. Metastasis is commonly present at diagnosis, with a Five-Year Survival Rate of

  • A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy
    Cancer Gene Therapy, 2020
    Co-Authors: Johanna Pruller, Isabella Hofer, Massimo Ganassi, Philipp Heher, Peter S. Zammit
    Abstract:

    Rhabdomyosarcoma is a rare childhood soft tissue cancer whose cells resemble poorly differentiated skeletal muscle, expressing myogenic proteins including MYOGENIN. Alveolar rhabdomyosarcoma (ARMS) accounts for ~40% of cases and is associated with a poorer prognosis than other rhabdomyosarcoma variants, especially if containing the chromosomal translocation generating the PAX3-FOXO1 hybrid transcription factor. Metastasis is commonly present at diagnosis, with a Five-Year Survival Rate of